1. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL,
Laster L. Enzymatic defect in Fabry’s disease: ceramidetrihexosidase deficiency. N Engl J Med. 1967;276:1163–7.
2. Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.
3. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara
M, et al. An atypical variant of Fabry’s disease in men with left
ventricular hypertrophy. N Engl J Med. 1995;333:288–93.
4. Elleder M, Bradová V, Smíd F, Budĕsínský M, Harzer K,
Kustermann-Kuhn B, et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry’s disease. Report on a
case simulating hypertrophic non-obstructive cardiomyopathy.
Virchows Arch A Pathol Anat Histopathol. 1990;417:449–55.
5. Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y,
Yoshida A, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int. 2003;64:801–7.
6. Anna A, Monika G. Splicing mutations in human genetic disorders: examples, detection, and confirmation. J Appl Genet.
2018;59:253–68.
7. Thusberg J, Olatubosun A, Vihinen M. Performance of mutation
pathogenicity prediction methods on missense variants. Hum
Mutat. 2011;32:358–68.
8. Jian X, Boerwinkle E, Liu X. In silico tools for splicing defect
prediction: a survey from the viewpoint of end users. Genet
Med. 2014;16:497–503.
9. Yamamura T, Horinouchi T, Aoto Y, Lennon R, Nozu K. The
contribution of COL4A5 splicing variants to the pathogenesis of X-linked Alport syndrome. Front Med (Lausanne).
2022;9:841391.
10. Horinouchi T, Nozu K, Yamamura T, Minamikawa S, Omori
T, Nakanishi K, et al. Detection of splicing abnormalities and
genotype-phenotype correlation in X-linked Alport syndrome.
J Am Soc Nephrol. 2018;29:2244–54.
11. Tsuji Y, Yamamura T, Nagano C, Horinouchi T, Sakakibara N,
Ishiko S, et al. Systematic review of genotype-phenotype correlations in Frasier syndrome. Kidney Int Rep. 2021;6:2585–93.
12. Aoto Y, Horinouchi T, Yamamura T, Kondo A, Nagai S, Ishiko
S, et al. Last nucleotide substitutions of COL4A5 exons cause
aberrant splicing. Kidney Int Rep. 2022;7:108–16.
13. Rossanti R, Horinouchi T, Yamamura T, Nagano C, Sakakibara
N, Ishiko S, et al. Evaluation of suspected autosomal Alport
syndrome synonymous variants. Kidney360. 2022;3:497–505.
14. Inoue T, Nagano C, Matsuo M, Yamamura T, Sakakibara N,
Horinouchi T, et al. Functional analysis of suspected splicing
variants in CLCN5 gene in Dent disease 1. Clin Exp Nephrol.
2020;24:606–12.
15. Tang R, Prosser DO, Love DR. Evaluation of bioinformatic programmes for the analysis of variants within splice site consensus
regions. Adv Bioinform. 2016;2016:5614058.
16. Wai HA, Lord J, Lyon M, Gunning A, Kelly H, Cibin P, et al.
Blood RNA analysis can increase clinical diagnostic rate
and resolve variants of uncertain significance. Genet Med.
2020;22:1005–14.
17. Wang Z, Burge CB. Splicing regulation: from a parts list of
regulatory elements to an integrated splicing code. RNA.
2008;14:802–13.
18. Wang GS, Cooper TA. Splicing in disease: disruption of the
splicing code and the decoding machinery. Nat Rev Genet.
2007;8:749–61.
19. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M,
Lander ES, Getz G, Mesirov JP. Integrative genomics viewer.
Nat Biotechnol. 2011;29:24–6.
745
20. Sakaguchi N, Suyama M. In silico identification of pseudo-exon
activation events in personal genome and transcriptome data.
RNA Biol. 2021;18:382–90.
21. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J,
et al. Standards and guidelines for the interpretation of sequence
variants: a joint consensus recommendation of the American
College of Medical Genetics and Genomics and the Association
for Molecular Pathology. Genet Med. 2015;17:405–24.
22. Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina
A, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab.
2018;123:416–27.
23. Seo J, Kim M, Hong GR, Kim DS, Son JW, Cho IJ, et al. Fabry
disease in patients with hypertrophic cardiomyopathy: a practical
approach to diagnosis. J Hum Genet. 2016;61:775–80.
24. Topaloglu AK, Ashley GA, Tong B, Shabbeer J, Astrin KH, Eng
CM, et al. Twenty novel mutations in the alpha-galactosidase A
gene causing Fabry disease. Mol Med. 1999;5:806–11.
25. Zizzo C, Monte I, Pisani A, Fatuzzo P, Riccio E, Rodolico MS,
et al. Molecular and clinical studies in five index cases with novel
mutations in the GLA gene. Gene. 2016;578:100–4.
26. Choi JH, Lee BH, Heo SH, Kim GH, Kim YM, Kim DS, et al.
Clinical characteristics and mutation spectrum of GLA in Korean
patients with Fabry disease by a nationwide survey: underdiagnosis of late-onset phenotype. Medicine. 2017;96:e7387.
27. Lee BH, Heo SH, Kim GH, Park JY, Kim WS, Kang DH, et al.
Mutations of the GLA gene in Korean patients with Fabry disease
and frequency of the E66Q allele as a functional variant in Korean
newborns. J Hum Genet. 2010;55:512–7.
28. Riera C, Lois S, Domínguez C, Fernandez-Cadenas I, Montaner
J, Rodríguez-Sureda V, de la Cruz X. Molecular damage in Fabry
disease: characterization and prediction of alpha-galactosidase A
pathological mutations. Proteins. 2015;83:91–104.
29. Nowak A, Mechtler TP, Hornemann T, Gawinecka J, Theswet E,
Hilz MJ, Kasper DC. Genotype, phenotype and disease severity
reflected by serum LysoGb3 levels in patients with Fabry disease.
Mol Genet Metab. 2018;123:148–53.
30. Shabbeer J, Yasuda M, Benson SD, Desnick RJ. Fabry disease:
identification of 50 novel alpha-galactosidase A mutations causing
the classic phenotype and three-dimensional structural analysis of
29 missense mutations. Hum Genom. 2006;2:297–309.
31. Cooper TA. Use of minigene systems to dissect alternative splicing elements. Methods. 2005;37:331–40.
32. Higuchi T, Kobayashi M, Ogata J, Kaneshiro E, Shimada Y, Kobayashi H, et al. Identification of cryptic novel α-galactosidase A
gene mutations: abnormal mRNA splicing and large deletions.
JIMD Rep. 2016;30:63–72.
33. Filoni C, Caciotti A, Carraresi L, Donati MA, Mignani R, Parini
R, et al. Unbalanced GLA mRNAs ratio quantified by real-time
PCR in Fabry patients’ fibroblasts results in Fabry disease. Eur J
Hum Genet. 2008;16:1311–7.
34. Ishii S, Nakao S, Minamikawa-Tachino R, Desnick RJ, Fan JQ.
Alternative splicing in the alpha-galactosidase A gene: increased
exon inclusion results in the Fabry cardiac phenotype. Am J Hum
Genet. 2002;70:994–1002.
35. Horinouchi T, Yamamura T, Minamikawa S, Nagano C, Sakakibara N, Nakanishi K, et al. Pathogenic evaluation of synonymous
COL4A5 variants in X-linked Alport syndrome using a minigene
assay. Mol Genet Genom Med. 2020;8:e1342.
36. Oliveira JP, Ferreira S. Multiple phenotypic domains of Fabry
disease and their relevance for establishing genotype- phenotype
correlations. Appl Clin Genet. 2019;12:35–50.
37. Dai X, Zong X, Pan X, Lu W, Jiang GR, Lin F. Identification and
functional characterization of the first deep intronic GLA mutation (IVS4+1326C>T) causing renal variant of Fabry disease.
Orphanet J Rare Dis. 2022;17:237.
13
746
38. Liao HC, Hsu TR, Young L, Chiang CC, Huang CK, Liu HC, et al.
Functional and biological studies of α-galactosidase A variants
with uncertain significance from newborn screening in Taiwan.
Mol Genet Metab. 2018;123:140–7.
39. Chiang HL, Wang NH-H, Song IW, Chang CP, Wen MS, Chien
YH, et al. Genetic epidemiological study doesn’t support GLA
IVS4+919G>A variant is a significant mutation in Fabry disease.
Mol Genet Metab. 2017;121:22–7.
40. Ferri L, Covello G, Caciotti A, Guerrini R, Denti MA, Morrone
A. Double-target antisense U1snRNAs correct mis-splicing due
to c.639+861C>T and c.639+919G>A GLA deep intronic mutations. Mol Ther Nucleic Acids. 2016;5:e380.
41. Chang WH, Niu DM, Lu CY, Lin SY, Liu TC, Chang JG. Modulation the alternative splicing of GLA (IVS4+919G>A) in Fabry
disease. PLoS ONE. 2017;12:e0175929.
42. Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel
E, Miebach E, et al. The Mainz Severity Score Index: a new
13
Clinical and Experimental Nephrology (2023) 27:737–746
instrument for quantifying the Anderson–Fabry disease phenotype, and the response of patients to enzyme replacement therapy.
Clin Genet. 2004;65:299–307.
43. Auray-Blais C, Blais CM, Ramaswami U, Boutin M, Germain DP,
Dyack S, et al. Urinary biomarker investigation in children with
Fabry disease using tandem mass spectrometry. Clin Chim Acta.
2015;438:195–204.
4 4. Lee SH, Li CF, Lin HY, Lin CH, Liu HC, Tsai SF, Niu DM. Highthroughput detection of common sequence variations of Fabry disease in Taiwan using DNA mass spectrometry. Mol Genet Metab.
2014;111:507–12.
Publisher's Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
...
論文の公開元へ
